Ryvu Therapeutics
Please note: The information displayed on this page might be outdated.
Ryvu Therapeutics :
Developer of targeted oncology therapies hematology/solid tumors. RVU120 is wholly-owned first-in-class oral CDK8/19 inhibitor in Phase I for AML/MDS with start-up of Phase Ib in solid tumors expected 3Q 2021. Company has small molecule, synthetic lethality platform in pre-clinical development including novel targets WRN and PRMT5. Ryvu's PIM/FLT3 kinase inhibitor in Phase 1/2 is partnered with Menarini.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Industry
Biotechnology, Pharmaceuticals
Investement Strategy
Under the Radar
Listing
Public
Therapeutic Modalities
Gene Therapy, Small Molecule
Website:
Profiles:
Address:
2 Sternbacha Street
Kraków, 30-394
Poland
Kraków, 30-394
Poland
More info:
My account:
Company Participants at Solebury Trout Hamptons CEO Roundtable 2021
- Vatnak Vat-Ho, Chief Business Officer
Top 10 Holders of Ryvu Therapeutics SA
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| PTE PZU SA | 10.87 | 1,994,695 | 0.00 | Funds | 12/31/21 |
| Norges Bank Investment Management | 6.35 | 1,164,840 | 0.00 | Funds | 12/31/21 |
| Aviva PTE Aviva Santander SA | 6.12 | 1,122,859 | 0.00 | Stakes | 8/18/21 |
| NN Investment Partners Towarzystwo Funduszy Inwestycyjnych SA | 0.05 | 8,780 | 0.00 | Funds | 5/31/21 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.